Skip Links

Directors' emoluments in 2009


The aggregate remuneration, excluding pension contributions and the value of shares under option and shares subject to Share Awards, paid to or accrued for all Directors for services in all capacities during the year ended 31 December 2009 was £6.2 million ($9.6 million). The remuneration of individual Directors is set out below in pounds sterling and US dollars. All salaries, fees, bonuses and other benefits for Directors are established in pounds sterling.

Directors' remuneration - pounds sterling

Name Salary
and fees
£000
Bonus
Cash
£000
Bonus
Shares1
£000
Taxable
benefits
£000
Other payments
and allowances
£000
Total
2009
£000

Total
2008
£000
Total
2007
£000
Louis Schweitzer 325 - - - - 325 303 260
David Brennan 9733 1,167 584 26 4362 3,186 2,506 2,150
Simon Lowth 550 550 275 8 434 1,4268 1,304 172
Bo Angelin 70 - - - - 70 63 21
John Buchanan 110 - - - - 110 96 69
Jean-Philippe Courtois 75 - - - - 75 58 -
Jane Henney 85 - - - - 85 76 57
Michele Hooper 100 - - - - 100 90 64
Rudy Markham 75 - - - - 75 23 -
Nancy Rothwell 92 - - - - 92 80 54
John Varley 95 - - - - 95 83 56
Marcus Wallenberg 60 - - - - 60 53 40
Former Directors                
John Patterson6 135 187 - 3 1215 4468 1,081 982
Håkan Mogren7 33 - - - - 33 100 100
Others - - - - - - - 463
Total 2,778 1,904 859 37 600 6,178 5,916 4,488

Directors' remuneration - US dollars

Name Salary
and fees
$000
Bonus
Cash
$000
Bonus
Shares1
$000
Taxable
benefits
$000
Other payments
and allowances
$000
Total
2009
$000

Total
2008
$000
Total
2007
$000
Louis Schweitzer 504 - - - - 504 567 520
David Brennan 1,5083 1,808 905 40 6762 4,937 4,692 4,300
Simon Lowth 852 852 426 12 674 2,2098 2,442 345
Bo Angelin 108 - - - - 108 118 42
John Buchanan 170 - - - - 170 180 138
Jean-Philippe Courtois 116 - - - - 116 109 -
Jane Henney 132 - - - - 132 142 114
Michele Hooper 155 - - - - 155 169 128
Rudy Markham 116 - - - - 116 43 -
Nancy Rothwell 143 - - - - 143 150 108
John Varley 147 - - - - 147 155 113
Marcus Wallenberg 93 - - - - 93 99 80
Former Directors                
John Patterson6 209 290 - 5 1885 6928 2,024 1,965
Håkan Mogren7 51 - - - - 51 187 200
Others - - - - - - - 929
Total 4,304 2,950 1,331 57 931 9,573 11,077 8,982
1
These figures represent that portion of the 2009 bonuses required to be deferred into Shares to be held for a three-year period, as explained in the Bonus share deferral requirements section.
2
Relates to relocation allowances, a car allowance and cash payments in respect of dividends accrued on vesting of LTI share plan awards.
3
This figure includes a sum of $83,000/£54,000 in respect of member contributions to the AstraZeneca Executive Deferred Compensation Plan which were paid into the plan by means of a salary sacrifice (see the Defined contribution arrangements section for further details).
4
Relates to remaining cash following selection of benefits within AstraZeneca's UK flexible benefits programme.
5
Relates to cash payments in respect of dividends accrued on vesting of LTI share plan awards and remaining cash following selection of benefits within AstraZeneca's UK flexible benefits programme.
6
Part-year only as ceased to be a Director on 31 March 2009.
7
Part-year only as ceased to be a Director on 30 April 2009.
8
Does not include a cash allowance received in lieu of pension (see the Defined contribution arrangements section for further details).
For John Patterson, member contributions to the AstraZeneca Pension Fund of only a minimal amount for 2009 were paid through salary sacrifice, and as such no employee contributions are shown above or included within emoluments.

In the tables above and in the Pensions section, salaries have been converted between pounds sterling and US dollars at the average exchange rate for the year in question. These rates were:

  GBP/USD
2009 0.645
2008 0.534
2007 0.500

Executive Directors were also granted Share Awards and Option Awards. Details of share options granted to, and exercised by, Directors and the aggregate of gains realised on the exercise of options, and of awards under the LTI plans, in the year are given in the Share options section and in the Gains by Directors on exercise of share options section.

No Director has a family relationship with any other Director.

AstraZeneca
at a glance

"We are focused on the discovery, development and commercialisation of prescription medicines for six important areas of healthcare"

Find out more

Download
Report

AstraZeneca Annual Report and Form 20-F Information 2009

English (PDF 5.8Mb)
Swedish (PDF 3.3Mb)